On March 21, 2007, a federal judge in the U.S. District Court for the District of New Jersey found that Pfizer Inc.'s patents for celecoxib, the active ingredient in Celebrex®, for formulations containing celecoxib and for methods of treatment using celecoxib are valid and enforceable, and are infringed by Teva Pharmaceuticals U.S.A., Inc. Teva sought to produce and market a generic version of Pfizer's blockbuster drug Celebrex® for the treatment of osteoarthritis and rheumatoid arthritis. The Court found that Teva failed to prove obviousness, inequitable conduct, a violation of the best mode requirement, or obvious-type double patenting by clear and convincing evidence. Thus, the patents-in-suit are neither invalid nor unenforceable, and Teva has infringed the patents.
The Kaye Scholer team included Daniel L. Reisner, Jeffrey H. Horowitz, Abigail L. Langsam and Daniel Forchheimer, all in the Patent Litigation Department, and scientific advisors Anthony Khong and Karl Dresdner.
Also of Interest
- Second Circuit Expands Split on Nominative Fair Use November 16, 2016 • Articles
- JUVE Handbuch Recommends Frankfurt Office and Lawyers November 14, 2016 • Recognitions
- US News–Best Lawyers Recognizes 32 Kaye Scholer Practices and 41 Lawyers November 1, 2016 • Recognitions
- Maier Plans Emergency Response with Fort Meade and Fort Detrick Commanders October 20, 2016 • Client Successes
- Winning the War: Strategies for Prevailing in Consumer Fraud and False Advertising... October 17, 2016 • Articles
- 3D Printing: New Legal Issues Emerge with the Technology’s Revolutionary Potential October 10, 2016 • Articles
- Consumer Products in the Age of Big Data October 4, 2016 • Articles
- Shape of Things to Come: Protecting Product Configuration and Packaging Design September 26, 2016 • Articles
- On the Road to a Safe and Secure Internet of Things: What Companies Should Do September 19, 2016 • Articles